Natco Pharma rose 4% to Rs 881.35 after the company announced the launch of the first generic version of Revlimid (lenalidomide capsules) in the US market.
Natco Pharma, along with its marketing partner Arrow International (an affiliate of Teva Pharmaceutical Industries), launched the first generic version of Revlimid (lenalidomide capsules) in 5mg, 10mg, 15mg, and 25mg strengths in the US market.The above strengths of lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone; certain myelodysplastic syndromes; and mantle cell lymphoma following specific prior treatment.
Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients.
On a consolidated basis, net profit of Natco Pharma rose 28.23% to Rs 80.40 crore on 57.80% rise in net sales to Rs 560.50 crore in Q3 December 2021 over Q3 December 2020.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU